We are building a pipeline of photoreceptor-targeted gene-agnostic gene therapies in the ocular space to bring relief to patients with blinding retinal disease.
This is centered on two approaches, SPVN06 (neuroprotection) and SPVN20 (neuroenhancement), aiming to restore visual function in blinding retinal disease.
Our Portfolio
AAV: Adeno Associated Virus; dAMD: dry Age-related Macular Degeneration; FIH: First In Human; GA: Geographic Atrophy; IVT: intravitreal; RP: Retinitis Pigmentosa; ROA: Route of administration SC: suprachoroidal; SRI: subretinal injection
Expanded Access Policy
SparingVision is a clinical-stage genomic medicine company developing gene therapies designed to preserve and restore vision in patients with degenerative retinal diseases.
Clinical trials are essential to evaluating the safety and effectiveness of investigational gene therapies and are the primary way patients may access these therapies prior to regulatory approval.
While expanded access (also known as early access programs) may be available in limited circumstances, SparingVision does not currently provide expanded access to any of its investigational gene therapies, given the early stage of our development programs.
Information about our ongoing clinical trials can be found at https://clinicaltrials.gov/.
For questions about this policy or about SparingVision, please contact info@sparingvision.com.
As development programs evolve and additional data become available, SparingVision may reevaluate this policy, in accordance with applicable laws and regulations.
SPVN06
SparingVision’s lead product, SPVN06, is a breakthrough gene-agnostic therapy designed to preserve sight and slow disease progression in patients with inherited retinal diseases (IRDs) and other blinding diseases such as age-related macular degeneration (AMD).
Learn More
SPVN20
SparingVision’s second program, SPVN20, is a gene-agnostic gene therapy designed to restore vision for people with blinding retinal disease.
Learn More
PARTNERS
